Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Epcoritamab Combo Receives Canadian Approval in R/R Follicular Lymphoma

25 September 2026 · By · Wire by Fusion42

Published

25 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

Canada

◆ Source

Read at cancernetwork.com →

◆ Verified

Fusion42 · 25 September 2026 · Fusion42 review

Health Canada approved epcoritamab in combination with lenalidomide and rituximab for relapsed/refractory follicular lymphoma based on the phase 3 EPCORE FL-1 trial, which showed a 79% reduction in risk of disease progression or death compared to lenalidomide and rituximab alone.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Canadian biotech founders in lymphoma treatment have a new regulatory door open with epcoritamab combos now approved. You can explore partnerships or trials leveraging this recognized novel therapy for relapsed/refractory follicular lymphoma.

◆ Coverage

1 source · 25 Sep 2026

◆ Related on Wire

◆ Topics

Biotechdrug-approvalfollicular-lymphomaepcoritamabclinical-trialhealthcanada